Market capitalization | $2.33m |
Enterprise Value | $-6.14m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.46 |
P/B ratio (TTM) P/B ratio | 0.48 |
Short interest | 15.03% |
As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.
1 Analyst has issued a forecast MyMD Pharmaceuticals Inc:
1 Analyst has issued a forecast MyMD Pharmaceuticals Inc:
Sep '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -16 -16 |
5%
5%
|
Net Profit | -7.08 -7.08 |
52%
52%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MyMD Pharmaceuticals, Inc. is a clinical stage pharmaceutical company which engages in extending healthy lifespan. It involves in developing and commercializing therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD. The company is headquartered in Baltimore, MD.
Head office | United States |
CEO | Christopher Chapman |
Founded | 1989 |
Website | tnfpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.